Inovio Pharmaceuticals (INO) Other Non-Current Liabilities (2010 - 2022)
Inovio Pharmaceuticals (INO) posted Other Non-Current Liabilities of $710348.0 for Q3 2022, up 4691.23% sequentially from $14826.0 in Q4 2021, and up 1007.48% YoY from $64141.0 in Q3 2021.
Inovio Pharmaceuticals (INO) Other Non-Current Liabilities (2010 - 2022) Analysis & Trends
Inovio Pharmaceuticals has reported Other Non-Current Liabilities for 13 years, with the latest figure at $710348.0 in Q3 2022.
- Quarterly Other Non-Current Liabilities rose 1007.48% year-over-year to $710348.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $710348.0 (up 1007.48% YoY) and the FY2021 annual result came in at $14826.0, down 74.29% from the prior year.
- Other Non-Current Liabilities rose to $710348.0 in Q3 2022 per INO's latest filing, from $14826.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $119.8 million in Q2 2020 and troughed at $14826.0 in Q4 2021.
- A 5-year average of $9.8 million and a median of $75795.0 in 2018 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2020 and 2021: Other Non-Current Liabilities jumped 235895.43% in 2020, then tumbled 99.95% in 2021.
- Over 5 years, Other Non-Current Liabilities stood at $87333.0 in 2018, then jumped by 9998.16% to $8.8 million in 2019, then plunged by 99.35% to $57663.0 in 2020, then plunged by 74.29% to $14826.0 in 2021, then jumped by 4691.23% to $710348.0 in 2022.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $710348.0, $14826.0, and $64141.0 for Q3 2022, Q4 2021, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 710,348.00 |
| Dec 31, 2021 | 14,826.00 |
| Sep 30, 2021 | 64,141.00 |
| Jun 30, 2021 | 64,141.00 |
| Mar 31, 2021 | 64,141.00 |
| Dec 31, 2020 | 57,663.00 |
| Sep 30, 2020 | 39,776.00 |
| Jun 30, 2020 | 119.80 Mn |
| Mar 31, 2020 | 22.04 Mn |
| Dec 31, 2019 | 8.82 Mn |
| Sep 30, 2019 | 4.50 Mn |
| Jun 30, 2019 | 50,762.00 |
| Mar 31, 2019 | 64,257.00 |
| Dec 31, 2018 | 87,333.00 |
| Jun 30, 2018 | 228,665.00 |
| Mar 31, 2018 | 488,636.00 |
| Sep 30, 2017 | 940,341.00 |
| Jun 30, 2017 | 1.36 Mn |
| Mar 31, 2017 | 1.05 Mn |
| Dec 31, 2016 | 1.17 Mn |